Current principles of follicular lymphoma treatment

Over the last 10-15 years, prognosis of patients with follicular lymphoma has improved, and for majority patients, is a chronic disease ten years overall survival around 80%. Nevertheless, certain subset belongs to high-risk early relapses progressive disease, poor outcomes, much shorter survival, there still no standard approach in treatment lymphoma. Treatment highly heterogeneous, ranging from ?watch wait? strategy intensive immunochemotherapy, needs be individualized each patient. An stage can treated involved-field radiotherapy, which curative potential. Follicular advanced an incurable disease. Standard first-line combination anti-CD20 antibody (rituximab) chemotherapy, followed by maintenance. In relapse, novel monoclonal antibody-obinutuzumab chemotherapy. The lenalidomide rituximab shows good results refractory lymphoma, but also as treatment. option elderly comorbidities monotherapy. Autologous or allogeneic stem cell transplantation may small group selected patients. past decade development targeted agents such phosphoinositide three kinase inhibitors immunotherapies (CD20/CD3 bispecific antibody, chimeric antigen receptor T therapy) demonstrate efficiency chemotherapy-free not only relapsed/refractory A better understanding clinical biological features necessary improve outcomes future.